Cover Image
市場調查報告書 - 229833

挪威的體外診斷市場上投資機會,分析及預測

Norway In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018

出版商 Global Markets Direct
出版日期 內容資訊 英文 154 Pages
價格
挪威的體外診斷市場上投資機會,分析及預測 Norway In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018
出版日期: 2013年01月07日 內容資訊: 英文 154 Pages
簡介

本報告提供挪威的體外診斷市場主要資料和市場區隔及不同分類的收益,企業佔有率,流通佔有率等調查結果,再加上主要企業簡介,為您概述為以下內容。

目錄

1. 目錄

  • 1.1 表格一覽
  • 1.2 圖表一覽

2. 簡介

  • 2.1 關於本報告

3. 體外診斷 - 挪威

  • 3.1 體外診斷, 挪威, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
  • 3.2 體外診斷, 挪威, 企業佔有率

4. 臨床化學檢驗 - 挪威

  • 4.1 臨床化學檢驗 整體收益 (實際成果及預測)
    • 4.1.1 臨床化學分析設備 收益 (實際成果及預測)
    • 4.1.2 尿液檢查 Analyzers 收益 (實際成果及預測)
  • 4.2 臨床化學檢驗 流通佔有率
  • 4.3 臨床化學檢驗, 挪威, 企業佔有率

5. 遺傳基因檢驗 - 挪威

  • 5.1 遺傳基因檢驗 整體收益 (實際成果及預測)
  • 5.2 遺傳基因檢驗 流通佔有率
  • 5.3 遺傳基因檢驗, 挪威, 企業佔有率

6. 血液檢驗 - 挪威

  • 6.1 血液檢驗 整體收益 (實際成果及預測)
    • 6.1.1 血液分析試劑 收益 (實際成果及預測)
    • 6.1.2 免疫血液學檢查 收益 (實際成果及預測)
    • 6.1.3 血液凝固檢查 收益 (實際成果及預測)
    • 6.1.4 簡易血液檢驗 收益 (實際成果及預測)
    • 6.1.5 血球計數器收益 (實際成果及預測)
  • 6.2 血液檢驗 流通佔有率
  • 6.3 血液檢驗, 挪威, 企業佔有率

7. 組織/細胞檢驗 - 挪威

  • 7.1 組織/細胞檢驗 整體收益 (實際成果及預測)
  • 7.2 組織/細胞檢驗 流通佔有率
  • 7.3 組織/細胞檢驗, 挪威, 企業佔有率

8. 免疫化學檢查 - 挪威

  • 8.1 免疫化學檢查 整體收益 (實際成果及預測)
    • 8.1.1 疾病專一 免疫化學檢查 收益 (實際成果及預測)
    • 8.1.2 藥物濫用/藥毒物檢驗 收益 (實際成果及預測)
    • 8.1.3 內分泌檢查 收益 (實際成果及預測)
    • 8.1.4 藥物治療監測 收益 (實際成果及預測)
    • 8.1.5 免疫化學分析儀 收益 (實際成果及預測)
  • 8.2 免疫化學檢查 流通佔有率
  • 8.3 免疫化學檢查, 挪威, 企業佔有率

9. 感染/免疫疾病檢驗 - 挪威

  • 9.1 感染/免疫疾病檢驗 整體收益 (實際成果及預測)
  • 9.2 感染/免疫疾病檢驗 流通佔有率
  • 9.3 感染/免疫疾病檢驗, 挪威, 企業佔有率

10. 微生物學培養檢驗 - 挪威

  • 10.1 微生物學培養檢驗 整體收益 (實際成果及預測)
  • 10.1.1 微生物檢驗設備 收益 (實際成果及預測)
  • 10.2 微生物學培養檢驗 流通佔有率
  • 10.3 微生物學培養檢驗, 挪威, 企業佔有率

11. 主要企業概要 - 挪威 體外診斷 市場

  • 11.1 F. Hoffmann-La Roche Ltd.
    • 11.1.1 企業概要
  • 11.2 Siemens Healthcare
    • 11.2.1 企業概要
  • 11.3 Abbott Laboratories
    • 11.3.1 企業概要
  • 11.4 Ortho-Clinical Diagnostics Inc.
    • 11.4.1 企業概要
  • 11.5 bioMerieux S.A.
    • 11.5.1 企業概要
  • 11.6 Beckman Coulter, Inc.
    • 11.6.1 企業概要
  • 11.7 Bio-Rad Laboratories, Inc.
    • 11.7.1 企業概要
  • 11.8 Sysmex Corporation
    • 11.8.1 企業概要
  • 11.9 Becton, Dickinson及Company
    • 11.9.1 企業概要
  • 11.10 Phadia AB
    • 11.10.1 企業概要
  • 11.11 Alere Inc.
    • 11.11.1 企業概要
  • 11.12 DiaSorin S.p.A
    • 11.12.1 企業概要
  • 11.13 Danaher Corporation
    • 11.13.1 企業概要
  • 11.14 DIAGNOSTICA STAGO, Inc.
    • 11.14.1 企業概要
  • 11.15 Thermo Fisher Scientific Inc.
    • 11.15.1 企業概要
  • 11.16 PerkinElmer, Inc.
    • 11.16.1 企業概要
  • 11.17 Qiagen N.V.
    • 11.17.1 企業概要
  • 11.18 Gen-Probe Incorporated
    • 11.18.1 企業概要
  • 11.19 Grifols, S.A.
    • 11.19.1 企業概要
  • 11.20 堀場製作所
    • 11.20.1 企業概要
  • 11.21 Immucor, Inc.
    • 11.21.1 企業概要
  • 11.22 Life Technologies Corporation
    • 11.22.1 企業概要
  • 11.23 Hologic, Inc.
    • 11.23.1 企業概要
  • 11.24 Cellestis Limited
    • 11.24.1 企業概要

12. 財務交易展望

  • 12.1 合作
    • 12.1.1 Skyline Diagnostics Enters Into Research Agreement With Clavis Pharma
    • 12.1.2 Biofortuna Enters Into 流通 Agreement With Abbott
    • 12.1.3 NorDiag Enters Into Agreement With Precision System Science

13. 附錄

  • 13.1 Global Markets Direct 調查方法
  • 13.2 調查對象的市場定義
    • 13.2.1 體外診斷
  • 13.3 二級研究
  • 13.4 主要研究
  • 13.5 資料的模式化
  • 13.6 預測
  • 13.7 專門委員會的驗證
  • 13.8 貨幣換算
  • 13.9 諮詢方式
  • 13.10 免責聲明

表格一覽

  • 表格 1: 體外診斷, 挪威, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
  • 表格 2: 體外診斷, 挪威, 整體收益 ($m), USD 以實額為基礎, 實際成果
  • 表格 3: 體外診斷, 挪威, 整體收益 ($m), USD 以實額為基礎,預測
  • 表格 4: 體外診斷, 挪威, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 5: 臨床化學檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 表格 6: 臨床化學檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 表格 7: 臨床化學分析設備, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 8: 臨床化學分析設備, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 9: 尿液檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 10: 尿液檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 11: 臨床化學檢驗, 挪威, 流通佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 12: 臨床化學檢驗, 挪威, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 13: 遺傳基因檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 表格 14: 遺傳基因檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 表格 15: 遺傳基因檢驗, 挪威, 流通佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 16: 遺傳基因檢驗, 挪威, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 17: 血液檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 表格 18: 血液檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 表格 19: 血液分析試劑, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 20: 血液分析試劑, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 21: 免疫血液學檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 22: 免疫血液學檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 23: 血液凝固檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 24: 血液凝固檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 25: 簡易血液檢驗, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 26: 簡易血液檢驗, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 27: 血球計數器, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 28: 血球計數器, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 29: 血液檢驗, 挪威, 流通佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 30: 血液檢驗, 挪威, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 31: 組織/細胞檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 表格 32: 組織/細胞檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 表格 33: 組織/細胞檢驗, 挪威, 流通佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 34: 組織/細胞檢驗, 挪威, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 35: 免疫化學檢查, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 表格 36: 免疫化學檢查, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 表格 37: 疾病專一 免疫化學檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 38: 疾病專一 免疫化學檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 39: 藥物濫用/藥毒物檢驗, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 40: 藥物濫用/藥毒物檢驗, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 41: 內分泌檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 42: 內分泌檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 43: 藥物治療監測, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 44: 藥物治療監測, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 45: 免疫化學分析儀, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 46: 免疫化學分析儀, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 47: 免疫化學檢查, 挪威, 流通佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 48: 免疫化學檢查, 挪威, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 49: 感染/免疫疾病檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 表格 50: 感染/免疫疾病檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 表格 51: 感染/免疫疾病檢驗, 挪威, 流通佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 52: 感染/免疫疾病檢驗, 挪威, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 53: 微生物學培養檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 表格 54: 微生物學培養檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 表格 55: 微生物檢驗設備, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 表格 56: 微生物檢驗設備, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 表格 57: 微生物學培養檢驗, 挪威, 流通佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 58: 微生物學培養檢驗, 挪威, 企業佔有率 各收益 ($m), USD 以實額為基礎
  • 表格 59∼62: 體外診斷, 挪威, 交易內容詳細內容
  • 表格 63: 美金V.S.該地貨幣, 挪威, 平均實質匯率

圖表一覽

  • 圖 1: 體外診斷, 挪威, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
  • 圖 2: 體外診斷, 挪威, 整體收益 ($m), USD 以實額為基礎, 實際成果
  • 圖 3: 體外診斷, 挪威, 整體收益 ($m), USD 以實額為基礎,預測
  • 圖 4: 體外診斷, 挪威, 企業佔有率 (%)
  • 圖 5: 臨床化學檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 圖 6: 臨床化學檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 圖 7: 臨床化學分析設備, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 8: 臨床化學分析設備, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 9: 尿液檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 10: 尿液檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 11: 臨床化學檢驗, 挪威, 企業佔有率 (%)
  • 圖 12: 遺傳基因檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 圖 13: 遺傳基因檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 圖 14: 遺傳基因檢驗, 挪威, 企業佔有率 (%)
  • 圖 15: 血液檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 圖 16: 血液檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 圖 17: 血液分析試劑, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 18: 血液分析試劑, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 19: 免疫血液學檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 20: 免疫血液學檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 21: 血液凝固檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 22: 血液凝固檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 23: 簡易血液檢驗, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 24: 簡易血液檢驗, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 25: 血球計數器, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 26: 血球計數器, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 27: 血液檢驗, 挪威, 企業佔有率 (%)
  • 圖 28: 組織/細胞檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 圖 29: 組織/細胞檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 圖 30: 組織/細胞檢驗, 挪威, 企業佔有率 (%)
  • 圖 31: 免疫化學檢查, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 圖 32: 免疫化學檢查, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 圖 33: 疾病專一 免疫化學檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 34: 疾病專一 免疫化學檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 35: 藥物濫用/藥毒物檢驗, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 36: 藥物濫用/藥毒物檢驗, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 37: 內分泌檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 38: 內分泌檢查, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 39: 藥物治療監測, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 40: 藥物治療監測, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 41: 免疫化學分析儀, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 42: 免疫化學分析儀, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 43: 免疫化學檢查, 挪威, 企業佔有率 (%)
  • 圖 44: 感染/免疫疾病檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 圖 45: 感染/免疫疾病檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 圖 46: 感染/免疫疾病檢驗, 挪威, 企業佔有率 (%)
  • 圖 47: 微生物學培養檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
  • 圖 48: 微生物學培養檢驗, 挪威, 收益 ($m), USD 以實額為基礎 不同市場區隔,預測
  • 圖 49: 微生物檢驗設備, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
  • 圖 50: 微生物檢驗設備, 挪威, 收益 ($m), USD 以實額為基礎 各子市場區隔,預測
  • 圖 51: 微生物學培養檢驗, 挪威, 企業佔有率 (%)
  • 圖 52: Global Markets Direct 調查方法

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Summary

Global Markets Direct's new report, "Norway In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018" provides key market data on the Norway In Vitro Diagnostics market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within seven market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on key recent developments.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Global Markets Direct's team of industry experts.

Scope

  • Market size and company share data for In Vitro Diagnostics market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
  • Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within seven market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.
  • 2011 company shares and distribution shares data for each of the seven market categories.
  • Global corporate-level profiles of key companies operating within the Norway In Vitro Diagnosticsmarket.
  • Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Ortho-Clinical Diagnostics Inc., bioMerieux S.A., Beckman Coulter, Inc. and others.

Reasons to buy

  • Develop business strategies by identifying the key market categories and segments poised for strong growth.
  • Develop market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the Norway In Vitro Diagnostics competitive landscape.
  • Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • What are the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. What is This Report About?

3. In Vitro Diagnostics In Norway

  • 3.1. In Vitro Diagnostics, Norway, Overall Revenue ($m) , USD Constant, 2004-2018
  • 3.2. In Vitro Diagnostics, Norway, Company Share (2010-2011)

4. Clinical Chemistry In Norway

  • 4.1. Clinical Chemistry Overall Revenue, (2004-2018)
    • 4.1.1. Clinical Chemisty Analyzers, Revenue (2004-2018)
    • 4.1.2. Urine Analysis, Revenue (2004-2018)
  • 4.2. Clinical Chemistry Distribution Share (2010-2011)
  • 4.3. Clinical Chemistry, Norway, Company Share (2010-2011)

5. Genetic Testing In Norway

  • 5.1. Genetic Testing Overall Revenue, (2004-2018)
  • 5.2. Genetic Testing Distribution Share (2010-2011)
  • 5.3. Genetic Testing, Norway, Company Share (2010-2011)

6. Haematology In Norway

  • 6.1. Haematology Overall Revenue, (2004-2018)
    • 6.1.1. Haematology Reagents, Revenue , (2004-2018)
    • 6.1.2. Immunohaematology, Revenue (2004-2018)
    • 6.1.3. Haemostasis, Revenue (2004-2018)
    • 6.1.4. Haematology Rapid Tests, Revenue (2004-2018)
    • 6.1.5. Haematology Cell Counters, Revenue (2004-2018)
  • 6.2. Haematology Distribution Share (2010-2011)
  • 6.3. Haematology, Norway, Company Share (2010-2011)

7. Histology And Cytology In Norway

  • 7.1. Histology And Cytology Overall Revenue, (2004-2018)
  • 7.2. Histology And Cytology Distribution Share (2010-2011)
  • 7.3. Histology And Cytology, Norway, Company Share (2010-2011)

8. Immuno Chemistry In Norway

  • 8.1. Immuno Chemistry Overall Revenue, (2004-2018)
    • 8.1.1. Disease Specific Immunochemistry, Revenue (2004-2018)
    • 8.1.2. Drugs of Abuse / Toxicology, Revenue (2004-2018)
    • 8.1.3. Endocrinology Tests, Revenue (2004-2018)
    • 8.1.4. Immunochemistry Rapid Tests, Revenue (2004-2018)
    • 8.1.5. Therapeutic Drug Monitoring, Revenue (2004-2018)
    • 8.1.6. Immunochemistry Analyzers, Revenue (2004-2018)
  • 8.2. Immuno Chemistry Distribution Share (2010-2011)
  • 8.3. Immuno Chemistry, Norway, Company Share (2010-2011)

9. Infectious Immunology In Norway

  • 9.1. Infectious Immunology Overall Revenue, (2004-2018)
    • 9.1.1. Infectious Immunology Rapid Tests, Revenue (2004-2018)
  • 9.2. Infectious Immunology Distribution Share (2010-2011)
  • 9.3. Infectious Immunology, Norway, Company Share (2010-2011)

10. Microbiology Culture In Norway

  • 10.1. Microbiology Culture Overall Revenue, (2004-2018)
    • 10.1.1. Microbiology Analyzers, Revenue (2004-2018)
  • 10.2. Microbiology Culture Distribution Share (2010-2011)
  • 10.3. Microbiology Culture, Norway, Company Share (2010-2011)

11. Overview of Key Companies in Norway In Vitro Diagnostics Market

  • 11.1. F. Hoffmann-La Roche Ltd.
    • 11.1.1. Company Overview
  • 11.2. Siemens Healthcare
    • 11.2.1. Company Overview
  • 11.3. Abbott Laboratories
    • 11.3.1. Company Overview
  • 11.4. Ortho-Clinical Diagnostics Inc.
    • 11.4.1. Company Overview
  • 11.5. bioMerieux S.A.
    • 11.5.1. Company Overview
  • 11.6. Beckman Coulter, Inc.
    • 11.6.1. Company Overview
  • 11.7. Sysmex Corporation
    • 11.7.1. Company Overview
  • 11.8. Bio-Rad Laboratories, Inc.
    • 11.8.1. Company Overview
  • 11.9. Becton, Dickinson and Company
    • 11.9.1. Company Overview
  • 11.10. Alere Inc.
    • 11.10.1. Company Overview
  • 11.11. Mindray Medical International Limited
    • 11.11.1. Company Overview
  • 11.12. Danaher Corporation
    • 11.12.1. Company Overview
  • 11.13. Qiagen N.V.
    • 11.13.1. Company Overview
  • 11.14. DiaSorin S.p.A
    • 11.14.1. Company Overview
  • 11.15. Diagnostica Stago, Inc.
    • 11.15.1. Company Overview
  • 11.16. Thermo Fisher Scientific Inc.
    • 11.16.1. Company Overview
  • 11.17. PerkinElmer, Inc.
    • 11.17.1. Company Overview
  • 11.18. Horiba, Ltd.
    • 11.18.1. Company Overview
  • 11.19. Gen-Probe Incorporated
    • 11.19.1. Company Overview
  • 11.20. Immucor, Inc.
    • 11.20.1. Company Overview
  • 11.21. Life Technologies Corporation
    • 11.21.1. Company Overview
  • 11.22. Grifols, S.A.
    • 11.22.1. Company Overview
  • 11.23. Cellestis Limited
    • 11.23.1. Company Overview
  • 11.24. Hologic, Inc.
    • 11.24.1. Company Overview

12. Appendix

  • 12.1. Global Markets Direct Research Methodology
  • 12.2. Definitions of Markets Covered in the Report
    • 12.2.1. In Vitro Diagnostics
  • 12.3. Secondary Research
  • 12.4. Primary Research
  • 12.5. Models
  • 12.6. Forecasts
  • 12.7. Expert Panel Validation
  • 12.8. Currency Conversion
  • 12.9. Contact Us
  • 12.10. Disclaimer

List of Tables

  • Table 1: In Vitro Diagnostics, Norway, Overall Revenue ($m) , USD Constant, 2004-2018
  • Table 2: In Vitro Diagnostics, Norway, Overall Revenue ($m), USD Constant, Historic, 2004-2011
  • Table 3: In Vitro Diagnostics, Norway, Overall Revenue ($m), USD Constant, Forecast, 2011-2018
  • Table 4: In Vitro Diagnostics, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011
  • Table 5: Clinical Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
  • Table 6: Clinical Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
  • Table 7: Clinical Chemisty Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 8: Clinical Chemisty Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 9: Urine Analysis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 10: Urine Analysis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 11: Clinical Chemistry, Norway, Distribution Share by Revenue ($m), USD Constant, 2010-2011
  • Table 12: Clinical Chemistry, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011
  • Table 13: Genetic Testing, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
  • Table 14: Genetic Testing, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
  • Table 15: Genetic Testing, Norway, Distribution Share by Revenue ($m), USD Constant, 2010-2011
  • Table 16: Genetic Testing, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011
  • Table 17: Haematology, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
  • Table 18: Haematology, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
  • Table 19: Haematology Reagents, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 20: Haematology Reagents, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 21: Immunohaematology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 22: Immunohaematology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 23: Haemostasis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 24: Haemostasis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 25: Haematology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 26: Haematology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 27: Haematology Cell Counters, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 28: Haematology Cell Counters, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 29: Haematology, Norway, Distribution Share by Revenue ($m), USD Constant, 2010-2011
  • Table 30: Haematology, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011
  • Table 31: Histology And Cytology, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
  • Table 32: Histology And Cytology, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
  • Table 33: Histology And Cytology, Norway, Distribution Share by Revenue ($m), USD Constant, 2010-2011
  • Table 34: Histology And Cytology, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011
  • Table 35: Immuno Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
  • Table 36: Immuno Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
  • Table 37: Disease Specific Immunochemistry, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 38: Disease Specific Immunochemistry, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 39: Drugs of Abuse / Toxicology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 40: Drugs of Abuse / Toxicology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 41: Endocrinology Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 42: Endocrinology Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 43: Immunochemistry Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 44: Immunochemistry Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 45: Therapeutic Drug Monitoring, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 46: Therapeutic Drug Monitoring, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 47: Immunochemistry Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 48: Immunochemistry Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 49: Immuno Chemistry, Norway, Distribution Share by Revenue ($m), USD Constant, 2010-2011
  • Table 50: Immuno Chemistry, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011
  • Table 51: Infectious Immunology, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
  • Table 52: Infectious Immunology, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
  • Table 53: Infectious Immunology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 54: Infectious Immunology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 55: Infectious Immunology, Norway, Distribution Share by Revenue ($m), USD Constant, 2010-2011
  • Table 56: Infectious Immunology, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011
  • Table 57: Microbiology Culture, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
  • Table 58: Microbiology Culture, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
  • Table 59: Microbiology Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Table 60: Microbiology Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Table 61: Microbiology Culture, Norway, Distribution Share by Revenue ($m), USD Constant, 2010-2011
  • Table 62: Microbiology Culture, Norway, Company Share by Revenue ($m), USD Constant, 2010-2011

List of Figures

  • Figure 1: In Vitro Diagnostics, Norway, Overall Revenue ($m) , USD Constant, 2004-2018
  • Figure 2: In Vitro Diagnostics, Norway, Overall Revenue ($m), USD Constant, Historic, 2004-2011
  • Figure 3: In Vitro Diagnostics, Norway, Overall Revenue ($m), USD Constant, Forecast, 2011-2018
  • Figure 4: In Vitro Diagnostics, Norway, Company Share (%), 2011
  • Figure 5: Clinical Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
  • Figure 6: Clinical Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
  • Figure 7: Clinical Chemisty Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 8: Clinical Chemisty Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 9: Urine Analysis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 10: Urine Analysis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 11: Clinical Chemistry, Norway, Company Share (%), 2011
  • Figure 12: Genetic Testing, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
  • Figure 13: Genetic Testing, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
  • Figure 14: Genetic Testing, Norway, Company Share (%), 2011
  • Figure 15: Haematology, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
  • Figure 16: Haematology, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
  • Figure 17: Haematology Reagents, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 18: Haematology Reagents, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 19: Immunohaematology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 20: Immunohaematology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 21: Haemostasis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 22: Haemostasis, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 23: Haematology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 24: Haematology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 25: Haematology Cell Counters, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 26: Haematology Cell Counters, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 27: Haematology, Norway, Company Share (%), 2011
  • Figure 28: Histology And Cytology, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
  • Figure 29: Histology And Cytology, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
  • Figure 30: Histology And Cytology, Norway, Company Share (%), 2011
  • Figure 31: Immuno Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
  • Figure 32: Immuno Chemistry, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
  • Figure 33: Disease Specific Immunochemistry, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 34: Disease Specific Immunochemistry, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 35: Drugs of Abuse / Toxicology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 36: Drugs of Abuse / Toxicology, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 37: Endocrinology Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 38: Endocrinology Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 39: Immunochemistry Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 40: Immunochemistry Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 41: Therapeutic Drug Monitoring, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 42: Therapeutic Drug Monitoring, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 43: Immunochemistry Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 44: Immunochemistry Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 45: Immuno Chemistry, Norway, Company Share (%), 2011
  • Figure 46: Infectious Immunology, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
  • Figure 47: Infectious Immunology, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
  • Figure 48: Infectious Immunology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 49: Infectious Immunology Rapid Tests, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 50: Infectious Immunology, Norway, Company Share (%), 2011
  • Figure 51: Microbiology Culture, Norway, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
  • Figure 52: Microbiology Culture, Norway, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
  • Figure 53: Microbiology Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
  • Figure 54: Microbiology Analyzers, Norway, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
  • Figure 55: Microbiology Culture, Norway, Company Share (%), 2011
  • Figure 56: Global Markets Direct Methodology
Back to Top